CCHFV vaccine development, current challenges, limitations, and future directions

Büşra Ahata; Günseli Bayram Akçapınar

doi:10.3389/fimmu.2023.1238882

CCHFV vaccine development, current challenges, limitations, and future directions

Front Immunol. 2023 Sep 11:14:1238882. doi: 10.3389/fimmu.2023.1238882. eCollection 2023.

Authors

Büşra Ahata^{1

2}, Günseli Bayram Akçapınar¹

Affiliations

¹ Department of Medical Biotechnology, Institute of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Türkiye.
² Health Institutes of Turkey, Istanbul, Türkiye.

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is the most prevalent tick-borne viral disease affecting humans. The disease is life-threatening in many regions of the developing world, including Africa, Asia, the Middle East, and Southern Europe. In line with the rapidly increasing disease prevalence, various vaccine strategies are under development. Despite a large number of potential vaccine candidates, there are no approved vaccines as of yet. This paper presents a detailed comparative analysis of current efforts to develop vaccines against CCHFV, limitations associated with current efforts, and future research directions.

Keywords: Crimean-Congo hemorrhagic fever virus; DNA-based vaccines; mRNA-based vaccines; vaccines; viral vectored vaccines; virus-like particle (VLP).

Publication types

Review

MeSH terms

Africa / epidemiology
Asia / epidemiology
Hemorrhagic Fever Virus, Crimean-Congo*
Hemorrhagic Fever, Crimean* / epidemiology
Hemorrhagic Fever, Crimean* / prevention & control
Humans
Vaccine Development